Senior EHS Expert - Risk Management & Technical Safety
About the job
- The candidate must have 5 to 8 years of relevant professional experience in technical safety, process safety, risk engineering, or EHS in a technically demanding environment.
- The candidate must have demonstrated experience moderating risk analyses and hazard assessments.
- The candidate must have experience with incident investigations and root-cause methods.
- The candidate must have experience supporting technical projects.
- The candidate must have experience coaching, mentoring, or technically guiding specialists.
- The candidate must have studied safety engineering, engineering, chemistry, process engineering, environmental science, or a comparable field.
- The candidate must have sound knowledge of ISO 45001, risk management, technical safety, machinery and plant safety, and hazardous materials management.
- The candidate must have business-fluent German and very good spoken and written English.
- Take technical responsibility for risk management and technical safety at the Bern site.
- Serve as a subject matter expert for risk management, technical safety, and incident investigation, and support technical projects throughout their lifecycle.
- Work closely with Engineering, Operations, Quality, and EHS, and advance the site's safety standards.
- Provide technical support and development to EHS specialists and advise managers and project teams.
- Facilitate and conduct risk analyses and hazard assessments, including HAZOP, Bow Tie, Failure Mode and Effects Analysis, and Job Safety Analysis.
- Build and develop the site-wide risk register.
- Develop risk mitigation strategies for processes, facilities, and activities.
- Ensure consistent approaches in accordance with ISO 45001 and CSL Technical Standards.
- Conduct technical safety assessments.
- Lead pSIF investigations and root-cause analyses using ICAM, TapRooT, and root-cause analysis methods.
- Define and track sustainable preventive measures.
- Incorporate lessons learned into standards, standard operating procedures, and training.
- Provide EHS support for construction, modernization, and plant projects.
- Participate in design reviews, HAZOPs, pre-startup safety reviews, change controls, and technical acceptances.
- Ensure compliance with global technical standards.
- Coordinate EHS activities technically within project environments.
- Provide technical support and mentoring to EHS specialists.
- Advise managers and project teams on technical risks.
- Facilitate workshops and risk-based decision-making processes.
- Promote a sustainable safety and risk culture.
- Ensure compliance with ISO 45001, Swiss legislation, and CSL standards.
- Develop processes, standards, and work instructions.
- Support audits, inspections, and interactions with authorities.
About the company
CSL is a global biotechnology company that develops and delivers biotherapies and influenza vaccines. It focuses on plasma-derived and recombinant therapies for rare and serious diseases and sells to healthcare providers, hospitals, and governments across the Americas, Asia Pacific, and Europe. Its product range includes treatments for rare diseases, influenza vaccines, and antivenoms, produced through its R&D, manufacturing, and distribution operations. CSL differentiates itself by offering the broadest portfolio of plasma-derived and recombinant therapies and by leveraging its global footprint and emphasis on diversity to reach diverse markets. The company’s main goal is to save lives and protect health by expanding access to high-quality therapies and vaccines worldwide.
Company Size
10,001+
Company Stage
IPO
Headquarters
Parkville, Australia
Founded
1916
Get referred to CSL
See people who can refer or advise you
Simplify's Take
What believers are saying
- CSL reported US$176 million FY26 cost savings, ahead of its transformation target.
- US military flu-vaccine exceptions restored some demand after April 2026 mandate cuts.
- VarmX’s 2029 coagulation program gives CSL a new high-value pipeline beyond plasma.
What critics are saying
- FY26 statutory loss hit US$2.6 billion after US$7.1 billion impairments and restructuring.
- CSL plans US$400 million FY27 savings, implying more closures, layoffs, and execution friction.
- The U.S. plasma turnaround depends on Horizon 2; failure risks long-term margin collapse.
What makes CSL unique
- CSL’s FY26 revenue reached US$15.8 billion across plasma, vaccines, and Vifor.
- Seqirus’ AUJEMFLU won UK and European approvals, backed by Lancet Phase 3 data.
- HEMGENIX remains Europe’s first approved hemophilia B gene therapy, strengthening CSL Behring.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Time Off
Paid Vacation
Paid Sick Leave
Paid Holidays
Growth & Insights and Company News
6 month growth
0%1 year growth
0%2 year growth
1%Haemonetics shares jumped 12% after the company announced CSL now expects to move all of its current US plasma collection centres to Haemonetics' NexSys devices by the end of 2027. The deal, first disclosed in August, was initially limited to only a portion of CSL's US centres with no timeline. The expanded agreement is significant because losing CSL previously flattened Haemonetics' growth. In fiscal 2026, the company's organic revenue growth was just 1.1%, compared to 9.5% excluding lost CSL sales. Following the surge, Haemonetics trades at approximately 21 times forward earnings, above its five-year average of 19.1 times. The deal is non-exclusive with no minimum purchase requirements, meaning CSL can still modify scope and timing. Management plans to provide further details during its November earnings call.
CSL has raised US$1.5 billion through corporate bonds issued in the United States to refinance existing debt. The Australian biotechnology company turned to offshore debt markets for the transaction. The bond issuance allows CSL to manage its capital structure by replacing current borrowings with new financing secured from US investors.
Melbourne, Australia – 16 September 2025 CSL today announced it has entered into a strategic collaboration with privately held Dutch biotech company VarmX BV to support the company’s...
CSL Seqirus has published Phase 3 study results in The Lancet Infectious Diseases for its MF59-adjuvanted cell-based higher-dose quadrivalent influenza vaccine for older adults. The vaccine, marketed as AUJEMFLU, combines three proven approaches: MF59 adjuvant, cell-based manufacturing, and higher-dose formulation. The randomised study enrolled 7,699 adults aged 50 and older across eight countries. Results demonstrated superiority versus an adjuvanted egg-based comparator across all four influenza strains and age groups. The vaccine showed non-inferiority versus a recombinant vaccine for three of four strains in the 50-plus age group and all four strains in those aged 65-plus. The trivalent formulation received approval from the UK's MHRA and the European Commission earlier this year for adults aged 50 and above. Regulatory submissions have been made in multiple markets.
Australian biopharmaceutical company CSL reported a 2% decline in annual profit on Tuesday, as its core plasma division experienced falling revenue. The company posted an underlying net profit after tax of $3.14 billion on a constant currency basis for the year ended 30 June, down from $3.22 billion the previous year. CSL is among the world's leading flu vaccine manufacturers. The results reflect challenges in the plasma business, which forms a significant part of the company's operations.